| abstract |
The invention relates to compounds represented by the formula: A (CH2) nO-B, in which: A represents a C4-C8 alkyl, a phenoxyethyl, a phenoxyphenyl or a group having the formula (a) or (b), where X represents -N- or (c), Z represents (d), (e), (f), (g), -S- or -O-, R1 represents hydrogen, lower alkyl, phenyl or phenyl substituted by trifluoromethyl, R2 represents hydrogen or lower alkyl or R1 and R2 together form a closed chain of benzene, R3 represents hydrogen or lower alkyl; n is 1 or 2; B represents a group having the formula (h), (i), (j) or (k), where R4 represents -CO2R2, (l), (m), (n), (o) or (p), m is equal to a number between 0 and 3, R5 represents (q), phenyl or phenyl substituted by a halo, lower alkylthio, lower alkylsulfinyl or lower alkyl sulfonyl, R6 represents A (CH2) no- or a halo, provided that when R6 represents a halo, R5 represents (r), R7 represents lower alkyl, Y represents -CH2- or -O-, R8 represents lower alkyl or - (CH2) mCO2R3; R9 represents (s) or -CH2R10, R10 represents a lower alkyl, a phenyl, a phenyl substituted by a carboxy, a halo, a lower alkylthio or a lower alkylsulfinyl, a pyridyl, a furanyl or a quinolinyl, R11 represents an alkyl or lower phenyl; as well as the pharmacologically acceptable salts of such compounds, and their use in the treatment of inflammatory conditions, such as rheumatoid arthritis, ulcerative colitis, psoriasis and other immediate hypersensitivity reactions, in the treatment of obstructive states of the bronchonasal pathways developing via leukotriene, such as allergic rhinitis, allergic bronchial asthma and the like, and as gastric cytoprotective agents. |